DVS-233
Phase 3Small molecule
PfizerDVS-233 is one of 74 small molecule programs targeting Fibromyalgia. It is currently in Phase 3.
2
Indications
13
Total Trials
0
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Clozaril
LLife Extension Foundation Inc.
Phase 3
Comparator: Pbo
Merck & Co.Phase 3
Bupropion XL
GSKPhase 3
Brenipatide
Eli LillyPhase 3
Venlafaxine ER
PfizerPhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
Rapastinel
AbbViePhase 3
TC-5214
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Major Depressive Disorder9 trials
Show 6 more trials
Menopause3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DVS-233. EMBL-EBI & Wellcome Sanger Institute.
- [4]